ImmunityBio, Inc. (IBRX)

6.80 -0.24 (-3.34%) 收市：04:00PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 628

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	865.34k	無	1953
Mr. Richard Gerald Adcock	President, CEO & Director	1.16M	無	1969
Mr. David C. Sachs	Chief Financial Officer	824.62k	無	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	無	無	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	無	無	無
Ms. Regan J. Lauer	Chief Accounting Officer	無	無	1970
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	無	無	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	無	無	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	無	無	無
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

公司管治

截至 2024年5月1日 止，ImmunityBio, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：9；股東權利：6；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。